NASHUA, N.H., July 30 /PRNewswire-FirstCall/ -- iCAD(R), Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced that its SecondLook(R) Digital CAD technology customized for use with Sectra’s MicroDose Mammography(TM) system is now available throughout Europe.
“Adding the benefits of iCAD’s technology to Sectra’s digital mammography systems enhances the screening mammography experience exponentially for the radiologist,” said Dr. Jean-Claude Piguet from ImageRive, the official and exclusive institution of postgraduate studies for the Universite de Geneve. “Sectra’s Photon-Counting Technology provides a clearer, easier-to-read image due to high resolution, high DQE and low electronic noise. When coupled with iCAD’s SecondLook Digital CAD to identify areas of interest for closer consideration, the solution significantly improves workflow and increases the detection of cancer.”
iCAD has received CE mark approval to market and sell its customized solution with Sectra’s mammography systems and units have been placed at ImageRive Radiology Institute in Switzerland and Aarhus Hospital in Denmark.
“The availability of our CAD technology with Sectra solutions throughout Europe is a milestone in iCAD’s business strategy outside the US,” said Ken Ferry, president and CEO of iCAD. “Our solid partnership with Sectra, a leading provider of digital mammography systems in Europe, is a key element in our overall goal to increase the use of iCAD’s systems in this growing market.”
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Currently available in more than 2,200 healthcare centers worldwide, iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and, in the future, lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
About Sectra’s Medical Operations
Sectra develops and sells IT-systems and products for radiology, mammography and orthopedic departments. More than 950 hospitals worldwide use the system daily, together performing over 45 million radiology examinations annually. This makes Sectra one of the world leading companies within systems for handling digital radiology images. In Scandinavia, Sectra is the market leader with more than 50% of all film-free installations. Sectra’s systems have been installed in North America, Scandinavia and most major countries in Europe and the Far East.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
For iCAD, contact Darlene Deptula-Hicks at 603-882-5200 x7944, or via email at
CONTACT: Darlene Deptula-Hicks of iCAD, Inc., +1-603-882-5200, ext. 7944,
ddeptula@icadmed.com; or Investor Relations, Anne Marie Fields of
Lippert-Heilshorn & Associates for iCAD, Inc., +1-212-838-3777, ext. 6604,
icad@lhai.com; or Public Relations, Sara Morgan of Schwartz Communications
for iCAD, Inc., +1-781-684-0770, icad@schwartz-pr.com
Web site: http://www.icadmed.com/
